DK2905014T3 - Et intrauterint leveringssystem til præventionsmiddel - Google Patents

Et intrauterint leveringssystem til præventionsmiddel Download PDF

Info

Publication number
DK2905014T3
DK2905014T3 DK14193392.9T DK14193392T DK2905014T3 DK 2905014 T3 DK2905014 T3 DK 2905014T3 DK 14193392 T DK14193392 T DK 14193392T DK 2905014 T3 DK2905014 T3 DK 2905014T3
Authority
DK
Denmark
Prior art keywords
core
delivery system
membrane
poly
levonorgestrel
Prior art date
Application number
DK14193392.9T
Other languages
English (en)
Inventor
Bernd Duesterberg
Manja Ahola
Jyrki Pihlaja
Heikki Lyytikäinen
Harri Jukarainen
Satu Kleemola
Tero Parkatti
Tuula Valo
Ina Gröticke
Bernhard Lindenthal
Ulrike Fuhrmann
Original Assignee
Bayer Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40020198&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2905014(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Oy filed Critical Bayer Oy
Application granted granted Critical
Publication of DK2905014T3 publication Critical patent/DK2905014T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0039—Devices retained in the uterus for a prolonged period, e.g. intrauterine devices for contraception
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Communication Control (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Claims (4)

1. Intrauterint leveringssystem til den kontrollerede frigivelse af levonorgestrel over et længere tidsrum og ved et niveau krævet for præventionsmiddel, hvor det intrauterine leveringssystem omfatter en legemskonstruktion og mindst et reservoir omfattende en kerne og en membran omgivende kernen, hvor kernen og membranen i alt væsentligt består af en samme eller forskellig polymersammensætning, kendetegnet ved, at nævnte intrauterine leveringssystem omfatter levonorgestrel og endvidere indomethacin i stand til at forebygge eller undertrykke irregulær endometrieblødning, hvor levonorgestrel og indomethacin er i separate reservoirer og polymersammensætningerne af kernen og membranen er valgt fra gruppen bestående af - en polymersammensætning omfattende poly(dimethylsiloxan), - en polymersammensætning omfattende en siloxan-baseret polymer omfattende 3,3,3-trifluorpropylgrupper fastgjort til Si-atomerne af siloxanenhederne, - en polymersammensætning omfattende poly(alkylenoxid)-grupper, hvor nævnte poly(alkylenoxid)-grupper er til stede som alkoxy-terminerede grafts eller blokke forbundet til polysiloxanenhederne via silicium-kulstofbindinger, eller en blanding af disse former, og - en kombination af mindst to deraf.
2. Intrauterint leveringssystemet ifølge krav 1, kendetegnet ved, at fra 1 til cirka 50 % af substituenterne fastgjort til Si-atomerne af siloxanenhederne i den siloxan-baserede polymer er 3,3,3-trifluorpropylgrupper.
3. Intrauterint leveringssystemet ifølge krav 1, kendetegnet ved, at poly(alkylenoxid)-grupperne er poly(ethylenoxid)-grupper.
4. Levonorgestrel og indomethacin til anvendelse i en fremgangsmåde til prævention og til forebyggelse eller undertrykkelse af irregulær endometrieblødning og til at inducere amenorrhoe, hvor levonorgestrel og indomethacin frigives fra et intrauterint leveringssystem ifølge krav 1 over et længere tidsrum.
DK14193392.9T 2008-07-03 2009-07-01 Et intrauterint leveringssystem til præventionsmiddel DK2905014T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08397516A EP2140860A1 (en) 2008-07-03 2008-07-03 An improved method of contraception
EP09772630.1A EP2313084A4 (en) 2008-07-03 2009-07-01 INTRAUTERINE DISPOSAL SYSTEM FOR PREVENTION

Publications (1)

Publication Number Publication Date
DK2905014T3 true DK2905014T3 (da) 2018-06-25

Family

ID=40020198

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14193392.9T DK2905014T3 (da) 2008-07-03 2009-07-01 Et intrauterint leveringssystem til præventionsmiddel

Country Status (23)

Country Link
US (3) US20110146693A1 (da)
EP (3) EP2140860A1 (da)
JP (3) JP2011526609A (da)
KR (2) KR20110026516A (da)
CN (2) CN103976816A (da)
AR (1) AR072544A1 (da)
CA (1) CA2730040A1 (da)
CL (1) CL2009001490A1 (da)
CY (1) CY1120878T1 (da)
DK (1) DK2905014T3 (da)
ES (1) ES2673154T3 (da)
HR (1) HRP20180869T1 (da)
HU (1) HUE037520T2 (da)
LT (1) LT2905014T (da)
PE (1) PE20100057A1 (da)
PL (1) PL2905014T3 (da)
PT (1) PT2905014T (da)
SI (1) SI2905014T1 (da)
SM (1) SMT201800295T1 (da)
TR (1) TR201807996T4 (da)
TW (2) TW201002288A (da)
UY (1) UY31957A (da)
WO (1) WO2010000943A1 (da)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20080523A0 (fi) 2008-09-17 2008-09-17 Bayer Schering Pharma Oy Insertteri
FI20080524A0 (fi) 2008-09-17 2008-09-17 Bayer Schering Pharma Oy Insertteri
WO2010031902A1 (en) 2008-09-17 2010-03-25 Bayer Schering Pharma Oy An inserter
WO2012121811A1 (en) * 2011-03-04 2012-09-13 Arstat, Inc. Treatment of excessive menstrual blood loss by intravaginal administration of low doses of antifibronlytic or hemostatic agent
US10028858B2 (en) 2011-07-11 2018-07-24 Medicines360 Intrauterine systems, IUD insertion devices, and related methods and kits therefor
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US8633178B2 (en) 2011-11-23 2014-01-21 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
AR089765A1 (es) 2012-01-23 2014-09-17 Bayer Oy Un sistema para el suministro de un farmaco
TW201350122A (zh) * 2012-04-23 2013-12-16 Bayer Pharma AG １８－甲基－１５β，１６β－亞甲基－１９－降－２０－螺氧－４－烯－３－酮的子宮內用途，包含１８－甲基－１５β，１６β－亞甲基－１９－降－２０－螺氧－４－烯－３－酮的子宮內系統，及其於避孕及婦科治療之用途
USD718435S1 (en) 2012-05-30 2014-11-25 Medicines360 Intrauterine insertion device
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
SE539540C2 (sv) * 2013-09-12 2017-10-10 Qpharma Ab Ett läkemedelsavgivningssystem för en eller flera aktiva beståndsdelar
CA2927750A1 (en) * 2013-10-18 2015-04-23 Bayer Oy Intrauterine delivery system
EP3145489A1 (en) 2014-05-22 2017-03-29 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
WO2015189853A1 (en) 2014-06-13 2015-12-17 Meril Endo Surgery Private Limited An intrauterine device
TWI730948B (zh) * 2014-12-08 2021-06-21 芬蘭商拜耳股份有限公司 新穎的熱塑性聚胺甲酸酯，彼等材料於製造子宮內系統之ｔ-框架之用途及由此等材料製成之ｔ-框架
US20180008536A1 (en) * 2015-01-21 2018-01-11 Bayer Oy Drug delivery system comprising a non-steroidal anti-inflammatory (nsaid) and a progestogenic compound and methods for manufacturing
US20180140640A1 (en) 2015-04-22 2018-05-24 Cadens Beheer B.V. Improved contraceptive methods and compositions and devices for use therein
CN108135910B (zh) 2015-05-13 2022-12-02 拜耳股份有限公司 长效药物递送装置及其在避孕中的用途
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
CN108430453B (zh) * 2015-12-21 2023-03-17 拜耳股份有限公司 制造药物递送装置的方法和根据该方法制成的药物递送装置
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
GB2555373A (en) * 2016-08-23 2018-05-02 Reproductive Medicine And Gynaecology Associates Ltd Implant
AU201617347S (en) * 2016-12-23 2017-01-23 Jurox Pty Ltd intravaginal device
MX2020007323A (es) * 2017-09-27 2020-09-07 Bayer Oy Un metodo para modificar la liberacion de un agente terapeuticamente activo de una matriz elastomerica.
CN111770750B (zh) 2017-12-22 2024-05-10 阿利拉生物科技有限公司 痛经有关的疼痛和/或疼痛相关症状的治疗
US20200268932A1 (en) * 2019-02-22 2020-08-27 Arsenal Aaa, Llc. Crosslinkable polymer compositions
US20220168217A1 (en) * 2019-02-22 2022-06-02 Elkem Silicones USA Corp. Drug delivery silicone composition to improve active ingredient elution
KR102260999B1 (ko) * 2019-03-27 2021-06-04 (주)엠케어코리아 난소암 검사용 임플란트 및 이를 포함하는 검사킷 및 이를 이용한 난소암 검사방법
CA3139771A1 (en) 2019-05-31 2020-12-03 Susan Florence Evans Methods, compositions and devices for treating neuroinflammatory conditions
CN110215447A (zh) * 2019-06-14 2019-09-10 上海市计划生育科学研究所 甲芬那酸在避孕药物中的应用及其制备的杀精避孕药物
US11571329B2 (en) 2019-11-21 2023-02-07 Coopersurgical, Inc. Packaging systems for implantable devices and related methods
FR3127699B1 (fr) * 2021-10-05 2024-07-26 Womed Système intra-utérin dégradable pour la libération prolongée d’un principe actif dans la cavité utérine
CN116807727B (zh) * 2023-08-29 2023-11-21 上海宇度医学科技股份有限公司 一种妇产科医师用临床取环器
WO2025106820A1 (en) * 2023-11-16 2025-05-22 University Of South Florida Method of preventing progesterone contraceptive-induced abnormal uterine bleeding (aub)

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3880991A (en) * 1969-03-24 1975-04-29 Brook David E Polymeric article for dispensing drugs
US4188951A (en) 1972-08-17 1980-02-19 Alza Corporation Intrauterine system embracing selected copolymeric membranes for administering beneficial agent
US4495934A (en) 1978-07-25 1985-01-29 Shaw Jr Seth T IUD Arrangement
US4284074A (en) * 1978-07-26 1981-08-18 Shaw Jr Seth T IUD Arrangement
AU538963B2 (en) 1979-07-09 1984-09-06 Seth Thomas Shaw Jr. Drug for use with an iud
FR2539027B1 (fr) 1983-01-07 1987-03-06 Levrier Marc Systeme endo-uterin contraceptif et therapeutique associant cuivre, argent, hormone naturelle et acide iso amino caproique
NL8603216A (nl) * 1986-12-17 1988-07-18 Kurz Karl Heinz Inrichting om in de uterus te plaatsen.
JP2590358B2 (ja) * 1988-03-01 1997-03-12 正雄 五十嵐 子宮内膜症治療用の子宮内又は膣内投与製剤
FR2695826B1 (fr) * 1992-09-21 1995-01-06 Theramex Nouvelles compositions pharmaceutiques à base de dérivés de nomégestrol et leurs procédés d'obtention.
FI94947C (fi) 1994-04-05 1995-11-27 Maillefer Nokia Holding Sovitelma lankamaisia tuotteita puolaavan koneen yhteydessä
FI97944C (fi) * 1994-07-05 1997-03-25 Leiras Oy Vaikuttavaa ainetta luovuttava laite
FI97947C (fi) 1994-09-27 1997-03-25 Leiras Oy Menetelmä lääkepreparaatin valmistamiseksi
AU3968597A (en) * 1996-08-02 1998-02-25 Children's Medical Center Corporation Method of regulating the female reproductive system through angiogenesis inhibitors
US6440445B1 (en) * 1996-09-30 2002-08-27 Brigham & Women's Hospital Methods and compounds for treatment of abnormal uterine bleeding
FI103051B (fi) 1997-08-22 1999-04-15 Schering Oy Uusia blokkikopolymeerejä ja niiden valmistus
FI107339B (fi) 1998-06-30 2001-07-13 Leiras Oy Lääkeaineiden läpäisynopeutta säätävä kalvo tai matriisi
US6056976A (en) 1998-11-12 2000-05-02 Leiras Oy Elastomer, its preparation and use
US20050033163A1 (en) 2001-04-24 2005-02-10 Impres Medical, Inc. Intrauterine implant and methods of use
DE10045380A1 (de) * 2000-09-14 2002-04-04 Schering Ag Verfahren zur Kontrazeption und dessen Darreichungsform
WO2002038159A1 (fr) * 2000-11-10 2002-05-16 Mitsubishi Pharma Corporation Medicaments pour l'hyperplasie endometriale
AU2002313517B2 (en) * 2001-08-31 2007-09-06 Bayer Schering Pharma Oy Drug delivery system
JP2003221338A (ja) * 2002-01-29 2003-08-05 Masao Igarashi 子宮腺筋症治療製剤
DE602004026173D1 (de) * 2003-04-29 2010-05-06 Gen Hospital Corp Verfahren und vorrichtungen für die verzögerte freisetzung von mehreren arzneimitteln
GB0320238D0 (en) 2003-08-29 2003-10-01 Medical Res Council Treatment of disease
FI123188B (fi) * 2005-04-05 2012-12-14 Bayer Oy Ultraäänellä havaittavissa oleva kohdunsisäinen järjestelmä
US7862552B2 (en) * 2005-05-09 2011-01-04 Boston Scientific Scimed, Inc. Medical devices for treating urological and uterine conditions
CN100441156C (zh) * 2006-09-30 2008-12-10 华中科技大学 一种复合材料宫内节育器

Also Published As

Publication number Publication date
TW201601699A (zh) 2016-01-16
PL2905014T3 (pl) 2018-10-31
SI2905014T1 (en) 2018-08-31
CY1120878T1 (el) 2019-12-11
AR072544A1 (es) 2010-09-08
US10532025B2 (en) 2020-01-14
UY31957A (es) 2010-01-29
TWI602556B (zh) 2017-10-21
SMT201800295T1 (it) 2018-07-17
HUE037520T2 (hu) 2018-09-28
EP2905014A1 (en) 2015-08-12
JP2011526609A (ja) 2011-10-13
TW201002288A (en) 2010-01-16
KR20110026516A (ko) 2011-03-15
LT2905014T (lt) 2018-07-10
KR20150136143A (ko) 2015-12-04
ES2673154T3 (es) 2018-06-20
PE20100057A1 (es) 2010-02-25
EP2313084A1 (en) 2011-04-27
EP2313084A4 (en) 2014-03-05
HRP20180869T1 (hr) 2018-08-24
CA2730040A1 (en) 2010-01-07
PT2905014T (pt) 2018-06-22
JP2016166245A (ja) 2016-09-15
US20110146693A1 (en) 2011-06-23
TR201807996T4 (tr) 2018-06-21
JP6008893B2 (ja) 2016-10-19
US20140127280A1 (en) 2014-05-08
JP2014129412A (ja) 2014-07-10
CL2009001490A1 (es) 2010-08-06
EP2905014B1 (en) 2018-04-25
CN103976816A (zh) 2014-08-13
US20180263899A1 (en) 2018-09-20
US9999592B2 (en) 2018-06-19
EP2140860A1 (en) 2010-01-06
WO2010000943A1 (en) 2010-01-07
CN102088954A (zh) 2011-06-08
KR101659530B1 (ko) 2016-09-23

Similar Documents

Publication Publication Date Title
DK2905014T3 (da) Et intrauterint leveringssystem til præventionsmiddel
CA2161950C (en) Subdermally implantable device
JP2012040400A (ja) プロゲステロン受容体モジュレーターを含有する徐放性組成物
JP2001524124A (ja) テストステロンおよびテストステロン前駆体の投与のための膣内薬物送達用具
US20160262923A1 (en) Intrauterine delivery system
WO2010133757A1 (en) Vaginal delivery system
Sam Controlled release contraceptive devices: a status report
US20170312219A1 (en) Method of contraception
EP2062569B1 (en) Vaginal delivery system
HK1197641A (en) An intrauterine delivery system for contraception
HK1157208A (en) An intrauterine delivery system for contraception
HK1221634A1 (zh) 子宫内递送系统